Santhera Raised CHF 27.7 Million of New Capital

Santhera Pharmaceuticals Holding AG / Santhera Raised CHF 27.7 Million of New Capital . Processed and transmitted by Nasdaq OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Liestal, Switzerland, August 7, 2015 - Santhera Pharmaceuticals (SIX: SANN) announces that it has completed the sale of 300,000 registered shares of common stock yielding an aggregate income of CHF 27.7 million (USD 28.3 million). The proceeds will be used to finance the commercial launch of Raxone® in Leber's Hereditary Optic Neuropathy (LHON) in Europe.

The newly created shares with a par value of CHF 1.00 were issued from the Company's conditional capital and were sold by the independent broker Kepler Chevreux within four days (August 3 to 6) at an average price of CHF 92.38 per share. As of today, Santhera has 5.51 million shares outstanding.

Christoph Rentsch, Chief Financial Officer of Santhera, stated: "This financing demonstrates the excitement of shareholders and investors about the progress and prospects of Santhera. We now have the financial resources to expedite the launch of Raxone for the treatment of LHON as soon as the marketing authorization will have been issued by the European Commission."

About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of orphan mitochondrial and neuromuscular diseases. Santhera develops Raxone®/Catena® as treatment for patients with Leber's Hereditary Optic Neuropathy (LHON), Duchenne Muscular Dystrophy (DMD) and primary progressive Multiple Sclerosis (ppMS) and omigapil for Congenital Muscular Dystrophy (CMD), all areas of high unmet medical need. In June 2015, the Committee for Medicinal Products for Human Use (CHMP) recommended granting a marketing authorization in Europe for Raxone® for the treatment of LHON. For further information, please visit the Company's website www.santhera.com.

Raxone^® and Catena^® are trademarks of Santhera Pharmaceuticals.

For further information, contact:
Thomas Meier, PhD, Chief Executive Officer                
Phone +41 61 906 89 64                                              
thomas.meier@santhera.com                                       

Christoph Rentsch, Chief Financial Officer
Phone +41 61 906 89 65
christoph.rentsch@santhera.com

US investor contact:                                                   
Hans Vitzthum, LifeSci Advisors, LLC                          
Phone +1 212 915 2568                                               
hans@lifesciadvisors.com                                             

US Public Relations contact:
Deanne Eagle, Planet Communications
Phone +1 917 837 5866
deanne@planetcommunications.nyc

Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

# # #

--- End of Message ---

Santhera Pharmaceuticals Holding AG
Hammerstrasse 49 Liestal Switzerland

ISIN: CH0027148649;